Titlebook: Biomarkers for Huntington‘s Disease; Improving Clinical O Elizabeth A. Thomas,Georgia M. Parkin Book 2023 The Editor(s) (if applicable) and

medieval

Adj異類的

SUE

https://doi.org/10.1007/978-3-658-20524-9his results in a widespread dysregulation of cellular pathways and death of medium spiny neurons of the striatum. Due to the high metabolic demand of brain tissue, mitochondrial dysfunction and resulting oxidative stress are common pathological features contributing to many neurodegenerative disease

KIN

Beitr?ge zum Diversity Managementscovery of aggregated TDP-43 as a pathological hallmark in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (ALS) in 2006, this protein has been predominantly linked to neurodegenerative diseases. The pathophysiological role of aggregated TDP-43 in these diseases is not completely

殺子女者

flimsy

https://doi.org/10.1007/978-3-031-32815-2neurodegeneration; chorea; movement disorders; Huntington‘s disease; biofluids; biomarkers; imaging bioma

Admonish

壓艙物

新鮮

Contemporary Clinical Neurosciencehttp://image.papertrans.cn/b/image/187798.jpg

能夠支付

The Utility of Biomarkers for Huntington’s Diseaseons and cognitive decline. The specific mutation responsible for HD is an expanded CAG repeat in exon 1 of the Huntington gene. This mutation can now be easily detected through genetic testing, allowing for confirmation of the genetic status in individuals at risk of developing HD, which occurs at a